Five things for pharma marketers to know: Monday, March 26, 2018

Ablynx drops vobarilizumab; Investors unimpressed by Biohaven migraine drug meeting benchmarks; Trump administration prison anti-opioid push relies on naltrexone.

from Most popular articles from Medical Marketing and Media https://ift.tt/2G79kA2